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Meta-Analysis of the Heterogeneity in Association of
DRD4 7-Repeat Allele and AD/HD: Stronger
Association With AD/HD Combined Type
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The purpose of this meta-analysis was to examine whether
association studies between attention deﬁcit/hyperactivity dis
order (AD/HD) and the dopamine receptor 4 gene 7-repeat
(DRD4 7R) allele vary systematically based on study character
istics. A total of 27 empirical studies with 28 distinct samples
using either case–control or family-based association analyses
were included. Consistent with previous meta-analytic work
[Gizer et al. (2009), Hum Genet 126:51–90], the DRD4 7R allele
was associated with AD/HD across studies (OR ¼ 1.33; 95%
CI ¼ 1.16–1.53, z ¼ 4.04, P ¼ 0.00005) and there was signiﬁcant
systematic variability among studies (Q ¼ 54.24; P ¼ 0.001;
I2 ¼ 50.22). To account for the variability among studies, sample
and study level covariates were examined. No differences in
overall effect size emerged between family-based and case–
control studies. However, the risk allele frequency in the control
population accounted for a signiﬁcant portion of the variance
in overall effect size within case–control studies. In addition,
evidence for the association between the DRD4 7R allele and
distinct AD/HD subtypes emerged across family-based and
case–control studies. The proportion of AD/HD, combined type
individuals within the AD/HD sample was associated with a
signiﬁcant increase in the magnitude of association between the
DRD4 7R allele and AD/HD. Conversely, an increase in the
proportion of AD/HD, predominantly inattentive type individ
uals within the AD/HD sample was associated with a decrease in
study effect size. Implications regarding AD/HD etiological and
phenotypic heterogeneity are discussed.
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INTRODUCTION
Attention deﬁcit/hyperactivity disorder (AD/HD) is characterized
by persistent, pervasive and developmentally inappropriate levels of
inattention, hyperactivity–impulsivity, or both that lead to clini
cally signiﬁcant impairment. The AD/HD phenotype is highly
heterogeneous and there has been much debate on how to appro
priately reduce phenotypic heterogeneity by creating diagnostic
subtypes or separate disorders [e.g., Milich et al., 2001]. According
to the DSM-IV, individuals are sub-grouped into AD/HD com
bined type (AD/HD-C) if they exhibit high levels of both inatten

tion and hyperactive-impulsive symptoms; AD/HD predominantly
inattentive type (AD/HD-I) if they display excessive inattention
only; and AD/HD predominantly hyperactive-impulsive type
(AD/HD-HI) if they show excessive hyperactive-impulsive symp
toms only. AD/HD-I is the most prevalent subtype in community
samples [e.g., Gaub and Carlson, 1997; DuPaul et al., 1998]. In
contrast, AD/HD-C tends to be the most prevalent subtype in
clinical populations, outnumbering AD/HD-I by 2:1 and AD/HD
HI by 3:1 [Lahey et al., 1994]. Given that AD/HD-HI is the least
prevalent subtype and lacks temporal stability [Lahey et al., 2005],
this subtype will not be further discussed in detail.
Although the speciﬁc etiology is not completely understood,
several factors associated with the development of AD/HD have
been identiﬁed. Evidence from family, twin, and adoption studies
suggest that genetic factors substantially contribute to the devel
opment of AD/HD [heritability estimate ¼ 0.76; Faraone et al.,
2005]. Molecular genetics research has attempted to identify genes
that increase susceptibility for the disorder. Consistent with the
dopamine deﬁcit hypothesis of AD/HD etiology [Levy, 1991], genes
associated with the dopamine system (e.g., DAT1 and DRD4) have
been major foci of study. The dopamine receptor 4 gene 7 repeat
(DRD4 7R) allele has been widely studied and is one of the most
strongly associated alleles with AD/HD [OR ¼ 1.33; Gizer et al.,
2009].
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The DRD4 gene is a 48-bp VNTR on exon 3, located on
chromosome 11p15.5 [Gelernter et al., 1992; Petronis et al.,
1993]. Allele variants produce structural differences in the 3rd
intracellular loop of the D4 receptor, which belongs to the D2
receptor family, and couples to pre- and post-synaptic G-protein
effectors. D4 receptors are found at high densities in the frontal
cortex, amygdala, hippocampus, hypothalamus, and mesencepha
lon [Van Tol et al., 1991; O’Malley et al., 1992], and the 7R allele may
be associated with a sub-sensitive post-synaptic D4 receptor or
hypofunctioning of mesolimbic and mesocortical dopamine
branches [Missale et al., 1998]. Ten alleles (2R-11R) have been
identiﬁed in the global population [Seeman and Van Tol, 1994]
with the 2R, 4R and 7R alleles being the most common variants.
DRD4 allele frequency varies substantially between ethnic
groups [Chang et al., 1996]. Generally, the 7R allele is
relatively most prevalent in Central and South American popula
tions, less prevalent in European Ancestry populations, and least
prevalent in Asian populations [Van Tol et al., 1991; Chang
et al., 1996].
Despite an overall association between the DRD4 7R allele and
AD/HD, a recent meta-analysis [Gizer et al., 2009] found that the
magnitude of the association varies substantially across studies.
Though many different potential sources of heterogeneity exist,
researchers have focused primarily on AD/HD subtype and, to a
lesser extent, study methodology.

deﬁant disorder (ODD) and found that the DRD4 7R allele tends to
be more strongly associated with AD/HD when comorbid with
ODD [Holmes et al., 2002; Kirley et al., 2004].
Such inconsistent ﬁndings may be related to the small sample
sizes and limited stability of the DSM-IV AD/HD subtypes overtime
[Lahey et al., 2005]; thus, this question may be better addressed in
the context of a mega-sample or meta-analysis [Faraone, 2008]. For
example, by combining 14 independent samples, Lowe et al. [2004]
demonstrated that the DRD5 148 bp allele was associated with AD/
HD-C and AD/HD-I but not AD/HD-HI. Similarly, I.D. Waldman
(personal communication, September 8, 2009) used summary
statistics between studies and found evidence for a stronger rela
tionship between DAT1 and 5HTTLPR risk alleles and AD/HD-C
compared to AD/HD-I.
Study methodology. Others have taken a between-studies ap
proach and explored whether study methodology moderates the
magnitude of effect size. Li et al. [2006] explored the heterogeneity
in effect sizes between association studies using study design
(case–control vs. family-based) as a moderating variable and
found that case–control studies had a signiﬁcantly higher mean
effect size than family-based studies. The authors suggest that
such differences may be the result of population stratiﬁcation
[Cardon and Bell, 2001] or differences between subjects
ascertained from case–control and family-based study designs
[West et al., 2002].

Factors Accounting for Heterogeneity in the
Association of DRD4 7R Allele With AD/HD

Summary and Hypotheses

AD/HD subtype. According to Sagvolden et al. [2005], hypofunctioning in the mesolimbic dopaminergic pathway is related to
hyperactivity–impulsivity, and hypofunctioning in the mesocort
ical dopaminergic pathway is related to poor executive functioning
and attentional processes. Given that the DRD4 7R allele is impli
cated in the hypofunctioning of both dopaminergic pathways
[Missale et al., 1998], it is likely that the DRD4 7R allele would
give rise to both inattention and hyperactivity–impulsivity symp
toms. Therefore, the DRD4 7R allele may be more strongly associ
ated with individuals with AD/HD-C compared to AD/HD-I.
Furthermore, youth with AD/HD and the 7R allele tend to have
a quicker response time [Manor et al., 2002; Langley et al.,
2004] and a more consistent reaction time to target stimuli
than AD/HD youth without the 7R allele [Swanson et al.,
2000; Manor et al., 2002; Bellgrove et al., 2005]. Therefore, it is
unlikely that the DRD4 7R allele is associated with AD/HD-I, as
a subset of individuals with AD/HD-I has a slowed reaction time
to target stimuli [e.g., Dereﬁnko et al., 2008]. However, ﬁndings
from studies that have examined the differential association
between the DRD4 7R allele and AD/HD subtypes and AD/HD
symptom dimensions have been inconsistent [Rowe et al., 1998,
2001; McCracken et al., 2000; Todd et al., 2001; Frank et al.,
2004]. Similarly, ﬁndings on the association between single nucle
otide polymorphisms in the DRD4 promoter region and AD/HD
symptom dimensions have also been inconsistent [Lasky-Su et al.,
2007, 2008].
A few researchers have examined the association of the DRD4 7R
allele and AD/HD with the presence or absence of oppositional

Given the differences in samples, assessment methodology and
study design, systematic variation in observed effect sizes [Gizer
et al., 2009] is likely to result from a combination of sample and
study characteristics. Building from previous meta-analyses that
have found signiﬁcant variation in the association between AD/HD
and the DRD4 7R allele [Li et al., 2006; Gizer et al., 2009], the
purpose of this study was to examine how certain sample and
study variables may moderate the association between DRD4 7R
allele and AD/HD. Of particular interest is the distribution of AD/
HD subtypes in identiﬁed samples. Thus, based on AD/HD etio
logical theory [Sagvolden et al., 2005], the following hypothesis was
made:
An increase in the proportion of individuals with AD/HD-C in the
AD/HD sample would be associated with an increase in magni
tude of association between AD/HD and the DRD4 7R allele.
Conversely, an increase in the proportion of AD/HD-I in the AD/
HD sample will be associated with a decrease in magnitude of
association between AD/HD and the DRD4 7R allele.
In addition, several exploratory moderators of the relationship
between DRD4 7R allele and AD/HD were examined. Given that
additional studies have been published since Li et al. [2006], the
moderator of study design (case–control and family-based) was re
examined. The allele frequency in cases and controls, the mean age
of the AD/HD sample, the proportion of males in the AD/HD
sample, diagnostic classiﬁcation system, and sample ethnicity were
also examined as potential moderators to the relationship between
DRD4 7R and AD/HD.

MATERIALS AND METHODS
Literature Search
First, computer searches were conducted using the PubMed and
PsycInfo search engines. Keywords associated with AD/HD phe
notype (ADHD, inattention and hyperactivity) were crossed with
words associated with the DRD4 7R allele (DRD4, D4DR, dopamine receptor) to identify relevant studies that were published
between January 1990 and July 2009. The author reviewed abstracts
and if the study included an AD/HD or related sample (e.g.,
hyperkinetic disorder) and had genotyped DRD4 then the full-text
article were retrieved. Next, the reference section of each full textarticle, including previous meta-analyses [Faraone et al., 2001,
2005; Maher et al., 2002; Li et al., 2006; Gizer et al., 2009], were
reviewed to ﬁnd additional studies that were not identiﬁed in the
computer search. All together, this approach yielded 44 studies that
provided data on the association between AD/HD and DRD4 7R
allele. Using a developed protocol (available upon request), data
from each study was extracted on two separate occasions by this
study’s author. Next, the separate protocols for each study were
compared, and the corresponding author(s) for each identiﬁed
study were sent the protocol, asked to clarify any discrepancies, and
asked to provide supplementary information including raw data to
compute the effect size and values for moderating variables of
interest. No additional studies were identiﬁed in correspondence
with corresponding authors.

Inclusion Criteria
A study was included in the meta-analysis if it met all of the
following criteria: (1) presented an association analysis between
the DRD4 7R allele and AD/HD using either case–control or familybased methods; (2) included (or the author provided) sufﬁcient
data to calculate an odds ratio (OR) and variance for the association
between AD/HD and the DRD4 7R allele; (3) reported data from an
independent sample or was the largest dataset in a set of studies with
overlapping samples; and (4) case–control studies employed
healthy individuals for their control sample. For studies that used
both case–control and family-based methods, results from
case–control analyses were reported. Finally, for moderating anal
yses, the study needed to provide a value for the relevant moderating
variable. For non-independent samples, the largest sample that
provided a value for the moderating variable was included.

Identiﬁed Studies
Of the 44 identiﬁed studies, a total of 17 studies were excluded from
the primary analysis. Five studies conducted with Asian popula
tions were excluded due to the absence of 7R alleles [Qian et al.,
2004; Brookes et al., 2005; Kim et al., 2005; Leung et al., 2005; Cheuk
et al., 2006]. Four studies were excluded because the OR corre
sponding to the association between the 7R allele and AD/HD could
not be computed [Manor et al., 2002; Bhaduri et al., 2006; Brookes
et al., 2006; Monuteaux et al., 2008]. Seven studies were excluded
due to partially overlapping samples with larger samples [Smalley
et al., 1998; Faraone et al., 1999; McCracken et al., 2000; Holmes
et al., 2002; Kirley et al., 2002; Grady et al., 2003; Johnson et al.,
2008]. Lowe et al. [2004] was also excluded from the primary

analysis but included in a moderating analysis as the proportion of
AD/HD subtypes could not be calculated in Hawi et al. [2000]. One
study was excluded because the control sample did not consist of
healthy individuals [Ballon et al., 2007]. Note that a number of
included case–control studies reported family-based association
ORs [Hawi et al., 2000; Holmes et al., 2000; Mill et al., 2001; Roman
et al., 2001; Gornick et al., 2007]. In these studies, only the data from
the case–control association analyses were reported as they were
associated with more precise sample information, included
more participants, and are comparable to family-based results
[Evangelou et al., 2006].
A total of 27 studies and 28 samples were included in the overall
meta-analysis. Sixteen case–control and 12 family-based samples
were included (see Tables IA and IB). AD/HD was diagnosed
according to DSM-IV criteria in the majority of studies. Smith
et al. [2003] did not use a formal diagnostic classiﬁcation system but
their sample approximated DSM-IV criteria for AD/HD-C or
ADHD-HI. Curran et al. [2001] used developmentally deviant
scores on a brief behavioral questionnaire. DSM-III criteria were
employed in three studies [Comings et al., 1999; Maher et al., 2002;
El-Faddagh et al., 2004]. Johansson et al. [2008] used the ICD-10
and made DSM-IV modiﬁcations allowing the sample to meet for
AD/HD-I. Swanson et al. [1998] required participants to meet both
DSM-IV and ICD-10 criteria.
Some studies applied additional inclusion criteria including: (1)
meeting criteria for DSM-IV AD/HD-C [LaHoste et al., 1996; Tahir
et al., 2000; Carrasco et al., 2006]; (2) a therapeutic response to
stimulant medication [Swanson et al., 1998; Sunohara et al., 2000
Irvine Sample]; (3) absence of comorbid psychiatric disorders
excluding ODD [Swanson et al., 1998; Muglia et al., 2000; Sunohara
et al., 2000 both Samples]; and (4) male gender [Swanson et al.,
1998]. Common exclusionary criteria included low IQ or the
presence of pervasive developmental disorder or neurological
disorder.
The majority of AD/HD samples were clinic-referred; three
samples were community-based [Curran et al., 2001; Todd et al.,
2001; El-Faddagh et al., 2004]. In addition, most samples were
child-based; two adult samples were included [Muglia et al., 2000;
Johansson et al., 2008]. In case–control studies, control samples
were selected using a variety of different methods including healthy
blood donors, healthy siblings, paternity testing services and
matched controls from epidemiological studies. In several studies,
AD/HD was not formally assessed in the control sample; thus, some
control subjects may have met diagnostic criteria for the disorder.

Effect Size and Within Study Variance
In case–control studies the OR is the ratio of the odds of having the
DRD4 7R allele to non-7R alleles in the ADHD group compared to
controls. Similarly, the OR for haplotype-based haplotype relative
risk (HHRR) studies was the ratio of the odds of parents transmit
ting the 7R allele to non-7R allele transmissions to AD/HD cases,
compared to the non-transmission of the DRD4 7R and non-7R
alleles. For transmission disequilibrium test (TDT) studies the
method reported by Lohmueller et al. [2003] was followed. Speciﬁ
cally, to compute the OR for TDT studies, the frequency that a
heterozygous parent passed on the DRD4 7R allele to their affected

Country
US
US
US
Ireland
UK
Canada
UK
UK
Brazil
US
Germany
US
Chile
US
Norway
Mexico

ADHD N
39
107
52
99
129
66
133
132
66
105
24
81
26
166
358
105

Control N
39
58
737
88
442
66
91
189
100
68
231
24
25
282
340
84

Age
—
9.4
—
—
—
34.3
—
10.4
10.1
—
4.5
—
—
9.0
33.9
14.3

Male
—
0.70
—
0.86
—
0.56
—
—
0.86
—
0.71
0.80
0.92
0.53
0.51
—

CT
1.00
0.65
—
—
0.76
—
—
0.91
0.77
—
—
—
1.00
0.94
0.21
—

IT
0.00
0.35
—
—
0.08
—
—
0.02
0.16
—
—
0.38
0.00
0.06
0.17
—

DRD4 7R frequency (ADHD)
0.28
0.24
0.18
0.24
0.22
0.21
0.26
0.21
0.25
0.20
0.33
0.30
0.19
0.23
0.22
0.30

DRD4 7R frequency (control)
0.12
0.13
0.14
0.26
0.13
0.10
0.14
0.14
0.17
0.20
0.19
0.25
0.14
0.17
0.24
0.35

Method
HHRR
HHRR
TDT
TDT
TDT
TDT
TDT
TDT
TDT
TDT
TDT
TDT
TDT

Country
US
Isreal
US
US
Canada
Turkey
US
US
Colombia
US
Ireland
Netherlands
Germany

ADHD N
52
47
17
59
88
29
201
33
—
535
178
236
49

Triads
52
—
4
21
75
26
201
33
—
535
—
231
36

Dyads
0
—
13
38
13
3
0
0
—
0
—
5
13

Age
—
9.89
—
—
—
—
—
—
—
11.0
—
—
8.4

Male
1.00
—
—
—
—
—
0.56
—
—
.74
—
—
0.88

CT
—
0.87
—
—
—
1.00
0.36
—
—
0.50
0.63
—
0.59

Age ¼ mean age of the AD/HD sample; Male ¼ proportion of males in the AD/HD sample; CT ¼ proportion of individuals with AD/HD-C in the sample; IT ¼ proportion of individuals with AD/HD-I in the sample.

References
Swanson et al. [1998]
Kotler et al. [2000]
Lunetta et al. [2000]
Sunohara et al. [2000], Irvine
Sunohara et al. [2000], Toronto
Tahir et al. [2000]
Todd et al. [2001]
Maher et al. [2002]
Arcos-Burgos et al. [2004]
Kustanovich et al. [2004]
Lowe et al. [2004]
Bakker et al. [2005]
Niederhofer et al. [2008]

IT
—
0.13
—
—
—
0.00
0.58
—
—
0.43
0.12
—
0.33

TABLE IB. Effect Size and Sample Characteristics for Family-Based Association Studies of the DRD4 7R Allele and AD/HD

Age ¼ mean age of the AD/HD sample; Male ¼ proportion of males in the AD/HD sample; CT ¼ proportion of individuals with ADHD-C in the AD/HD sample; IT ¼ proportion of individuals with AD/HD-I in the AD/HD sample.

References
LaHoste et al. [1996]
Rowe et al. [1998]
Comings et al. [1999]
Hawi et al. [2000]
Holmes et al. [2000]
Muglia et al. [2000]
Curran et al. [2001]
Mill et al. [2001]
Roman et al. [2001]
Smith et al. [2003]
El-Faddagh et al. [2004]
Frank et al. [2004]
Carrasco et al. [2006]
Gornick et al. [2007]
Johansson et al. [2008]
Martinez-Levy et al. [2009]

TABLE IA. Effect Size and Sample Characteristics for Case–Control Association Studies of the DRD4 7R Allele and AD/HD

OR (95% CI)
2.08 (1.06–4.06)
0.47 (0.22–.99)
1.50 (0.58–3.87)
1.00 (0.57–1.74)
1.52 (0.03–2.47)
1.90 (0.88–4.09)
1.11 (0.77–1.59)
1.13 (0.43–2.92)
1.13 (0.43–2.92)
1.21 (0.94–1.56)
1.35 (0.88–2.07)
1.06 (0.76–1.48)
0.92 (0.40–2.08)

OR (95% CI)
3.01 (1.29–7.05)
2.16 (1.16–4.04)
1.41 (0.84–2.37)
0.93 (0.58–1.49)
1.89 (1.33–2.70)
2.46 (1.21–5.00)
2.14 (1.30–3.52)
1.69 (1.11–2.56)
1.63 (.95–2.79)
0.98 (0.57–1.68)
2.19 (1.15–4.16)
1.26 (0.61–2.63)
1.46 (0.51–4.20)
1.45 (1.03–2.03)
0.90 (0.70–1.15)
0.77 (0.50–1.20)

offspring was divided by the frequency that the allele was not passed
to their affected offspring. Such a method is considered asymptoti
cally equivalent to calculating an OR in a case–control study, as in a
large population of control participants the expected transmission
ratio would approach 50:50 [Lohmueller et al., 2003]. The ORs for
both study types were then converted to log ORs and the log OR
variance within case–control and HHRR studies was calculated by
summing the reciprocals of the 7R allele and non-7R allele frequen
cies in cases and controls and for transmitted and non-transmitted
alleles, respectively. The variance in TDT studies was calculated
assuming a large control sample. Thus, the sum of the reciprocals
for the frequency of the transmitted risk allele and non-transmis
sion of the risk allele were considered asymptotically equivalent to
the sum of the reciprocal from each cell of a case–control study
[Lohmueller et al., 2003].

Statistical Analysis
Meta-analysis of case–control, HHRR and TDT studies was con
ducted using Comprehensive Meta-Analysis (Version 2.0, BIO
STAT, Englewood, NJ). Given that the samples and methods
employed between studies are variable, it is assumed that the effect
size from each study is a sample from a distribution of true effects
[Borenstein et al., 2009]. Thus, a random effects model was used to
estimate the mean of all relevant true effects [Borenstein et al., 2009]
and the mean effect of moderator variables. Compared to a ﬁxed
effects model, a random effects model allows inferences about
population parameters including the effect size and regression
coefﬁcients. The presence of heterogeneity in effect sizes between
studies was tested using the c2-based Q-statistic. Heterogeneity was
also measured with T2 and t which are estimates of the variance and
standard deviation of true effects using the DerSimonian and Laird
[1986] method. The amount of heterogeneity was quantiﬁed using
I2, which measures the proportion of total variation that reﬂects real
differences in the variability between studies in observed effect size
[Borenstein et al., 2009].
Subgroup analysis and meta-regression analyses were utilized to
examine the inﬂuence of categorical and continuous moderating
variables on observed effect size. Subgroup analyses utilized a
mixed-effects model, where T2 was calculated separately using a
random effects model within subgroups and using a ﬁxed effects
model between subgroups [Borenstein et al., 2009]. If a subgroup
had fewer than ﬁve studies, then T2 was pooled across subgroups
using a random-effects model, consistent with the recommenda
tion from Borenstein et al. [2009]. A Q-test was used to test for
heterogeneity across subgroups.
A method of moments meta-regression was used to calculate the
following model. Following notation by Raudenbush and Bryk
[2002]:dj ¼ g0 þ g 1 W1j þ uj þ ej where dj is the odds ratio of
study j, g 0 and g 1 are regression coefﬁcients; W1j is a study
characteristic predicting effect sizes (e.g., proportion of AD/HD
C individuals in a sample); and uj is the between studies random
error which is not predicted by the study characteristic for which we
assume uj � N (0, t2) and t2 is the between studies variance and ej is
sampling error associated with the estimate (i.e., dj) of the popula
tion effect size d, for study j, for which we assume ej � N (0, Vj). Here
Vj is considered ‘‘known’’ and is the sampling variance for dj. In this

FIG. 1. Forest plot of OR and pooled OR for association studies
between AD/HD and the DRD4 7R allele.

model, g 0 represents the estimated effect size when W1j is equal to
zero, and g 1 indicates the amount of change in the effect size for a
one-unit increase in W1j [Feinn et al., 2005]. Two-tailed z-tests were
used to assess the impact of the moderating variables on effect size.
An analogous index for proportion of variance explained was
calculated; (R2analog ¼ T2explained =T2Total ) to describe the proportion
of systematic, between studies variance that is explained by the
presence of the moderating variable [Borenstein et al., 2009]. Alpha
was set to 0.05 for hypothesized analyses and reduced to 0.007 for
exploratory meta-regression and sub-group analyses using a Bon
feronni adjustment.

RESULTS
See Tables IA and IB for a summary of included studies. Twentyeight independent samples met inclusion criteria to estimate the
mean effect size for the association between the DRD4 7R allele and
AD/HD. A total of 1,688 identiﬁed AD/HD cases and 2,864 control
subjects drawn from case–control studies were included in the
meta-analysis. In family-based studies, approximately 1,3461 af
fected individuals participated. Fewer individuals in each sample
were included in TDT analyses as they require a parent to be
heterozygous for the allele of interest.
In the absence of a moderating variable, the unconditional model
produced a log OR of 0.29 for g 0. This corresponds to an OR of
1.33 (95% CI ¼ 1.16–1.53, z ¼ 4.04, P ¼ 0.00005; Fig. 1). Neither
visual inspection of a funnel plot nor Egger’s funnel plot statistic
1

The number 1,346 reflects the combined sample size from family-based
studies with the exception of Arcos-Burgos et al. 2004 as the number of
individuals with AD/HD from this study was not reported.

TABLE II. Study Characteristics Examined as Potential Moderating Variables of Effect Size
Moderator
Transformeda proportion of AD/HD-C in AD/HD sample
Proportion of AD/HD-C in AD/HD sample
Transformedb proportion of AD/HD-I in AD/HD sample
Proportion of AD/HD-I in AD/HD sample
DRD4 7R allele frequency in AD/HD sample
7R Allele frequency in control sample
Proportion of AD/HD males in AD/HD sample
Log mean AD/HD age

g1
1.47
0.85
-0.88
-0.90
0.99
-5.02
0.52
-0.18

SE
0.55
0.28
0.38
0.43
2.72
0.92
0.81
0.21

z
2.67
3.02
-2.28
-2.09
0.37
-5.48
0.64
-0.85

dfresidual
13
13
13
13
14
14
8
10

P
0.008
0.003
0.023
0.037
0.715
0.000
0.523
0.396

The intercept for each analysis is not presented as the unconditional model demonstrated an overall association between the risk allele and the disorder, and the intercept for all moderating analyses
varied substantially. In addition, given that the coverage of some covariates near the intercept were lacking, estimates of the intercept were considered extrapolations beyond available data.a1/(2 - X).
b
HX.

[P ¼ 0.062; Egger et al., 1997] indicated the presence of publication
bias. In addition, Rosenthal’s fail-safe N suggests that 227
additional studies with a mean OR of 1.0 would need to be added
to the analysis before the effect would be no longer signiﬁcant. ORs
ranged from 1.30 to 1.36 and remained statistically signiﬁcant when
each study was removed from the analysis, one at time, indicating
that no one study produced the signiﬁcant overall effect. In the
unconditional model, the variability in observed effect size
between studies was greater than would be expected if each study
shared a common effect (Q ¼ 54.24; P ¼ 0.001). Furthermore, I2 ¼
50.22 suggests that approximately half of the observed variability in
effect size was systematic in nature. This indicates that moderating
variables, such as AD/HD subtype, may account for the heteroge
neity in effect sizes between studies. In order to test for this, the
unconditional model was expanded to include moderating varia
bles. Table II displays a summary of the results from these analyses.
To test the primary hypothesis that the DRD4 7R allele is more
strongly associated with AD/HD-C compared to other AD/HD
subtypes, the proportion of AD/HD-C individuals within the AD/
HD sample was entered into the equation as a moderating variable.
Given the proportional nature of this variable and that multiple
studies included only AD/HD-C individuals, the proportion of AD/
HD-C individuals within reporting studies was negatively skewed,
thus the reciprocal of 2 - X was applied to normalize the distribu
tion.2 Increases in the transformed proportion of AD/HD-C in
dividuals in the AD/HD sample predicted increases in the observed
log OR (see Fig. 2). The transformed proportion of AD/HD-C
individuals in the AD/HD sample accounted for 95% of the
systematic variability in the observed ORs between studies. This
was consistent with the untransformed proportion of AD/HD-C.
These ﬁndings were mirrored by the proportion of AD/HD-I
individuals in the AD/HD sample. The distribution of the propor
tion of the AD/HD-I variable was positively skewed and a square
root transformation was applied to normalize the distribution.3
Increases in the square root transformation of the proportion of

FIG. 2. Random-effects meta-regression analysis of study log OR
on the transformed proportion AD/HD-C individuals in the AD/HD
sample. The size of each data point reﬂects the relative weight of
each study.

AD/HD-I individuals in the AD/HD sample was associated with a
decreased log OR (see Fig. 3). This ﬁnding was consistent with the
effect of the non-transformed proportion of the AD/HD-I variable
on observed log OR.
Next, to explore whether study design accounted for variability
in effect size, studies were dichotomized into either case–control or
family-based design. Though effect sizes between studies were not
signiﬁcantly different (Q ¼ 2.76; P ¼ 0.097), case–control studies
had a larger mean effect size and a larger proportion of variability
in observed effects (OR ¼ 1.46; 95% CI ¼ 1.19–1.79; z ¼ 3.66;
P ¼ 0.0002; I2 ¼ 62.04) compared to family-based analyses
(OR ¼ 1.17; 95% CI ¼ 1.00–1.38; z ¼ 1.94; P ¼ 0.052; I2 ¼ 13.04).
Exploratory meta-regression analyses examined variability in
case–control studies. Allele frequency in the AD/HD sample did
not predict observed log OR, whereas increases in the allele fre
quency in the control sample was associated with decreases in the
observed log OR (see Fig. 4). Within case–control studies, the allele
frequency in the control sample accounted for approximately
100%4 of the systematic variability in observed effect size between

2

Where X is the proportion of individuals diagnosed with AD/HD-C.
When X ¼ 1 the proportion was revised to X1 ¼ 2v - 1/2v; where v is the
AD/HD sample size.
3
When the proportion of individuals with AD/HD-I was zero, the
proportion was revised to 1/2v; where v is the AD/HD sample size.

The R2analog theoretically ranges from 0 to 1 in the population;
however, sampling error may cause the index to fall outside this
range. In the present study, R2analog ¼ 1:30, the value was set to 1.0
[Borenstein et al., 2009].

4

FIG. 3. Random-effects meta-regression analysis of study log OR
on the transformed proportion of AD/HD-I individuals in the AD/
HD sample. The size of each data point reﬂects the relative
weight of each study.

FIG. 4. Random-effects meta-regression analysis of case–control
study log OR on the proportion of the DRD4 7R allele frequency in
the control sample. The size of each data point reﬂects the
relative weight of each study.

studies, whereas separately, the allele frequency in the AD/HD
population only accounted for 19%.
Exploratory analyses were also conducted to examine if other
variables were associated with the variability in effect sizes between
studies. In subgroup analyses, studies drawing from Mexico, Brazil,
Chile and Colombia were not signiﬁcantly different from other
studies (Q ¼ 0.07; P ¼ 0.407). In addition, studies using DSM-IV
were not signiﬁcantly different than studies using other diagnostic
approaches (Q ¼ 0.88; P ¼ 0.348). In meta-regression, neither the
proportion of males nor the log of the mean age of the AD/HD
sample5 predicted variability in observed effect size between studies.

DISCUSSION
The present meta-analysis examined the association of the DRD4
7R allele with AD/HD by combining 16 case–control and 12 familybased samples, which together included over 3,000 AD/HD cases
and over 2,800 controls. The overall mean OR between the DRD4
7R allele and AD/HD was 1.33. This indicates that the DRD4 7R
5

Mean age of the AD/HD sample was severely positively skewed. Thus a
log transformation was applied to normalize the distribution.

allele increases the odds that an individual is diagnosed with AD/
HD by 33%. This is in line with recent meta-analyses on the same
topic that used slightly different inclusion criteria [Faraone et al.,
2005; Li et al., 2006; Gizer et al., 2009].
Consistent with recent meta-analyses [Li et al., 2006; Gizer et al.,
2009], the magnitude of association varied signiﬁcantly between
studies. In an extension of previous topical meta-analyses and
consistent with this study’s primary hypothesis, increases in the
proportion of AD/HD-C individuals within the AD/HD sample
were associated with an increase in the magnitude of association
between the DRD4 7R allele and AD/HD. Findings suggest that
including only AD/HD-C individuals in an analysis would increase
the OR from 1.22 to 1.79, assuming 55% of the AD/HD sample met
criteria for AD/HD-C [Lahey et al., 1994]. Conversely, as the
proportion of AD/HD-I individuals in the AD/HD sample in
creased, the observed OR decreased. Taken together, results were
consistent with the hypothesis that the DRD4 7R allele is more
strongly associated with AD/HD-C compared to AD/HD-I. The
relative proportion of the two predominant AD/HD subtypes in the
AD/HD sample accounted for the majority of systematic variability
between reporting studies. Together, ﬁndings suggest that hypofunctioning in mesocortical and mesolimbic dopaminergic path
ways may better characterize the etiology of AD/HD-C compared to
AD/HD-I [Sagvolden et al., 2005]. This is in line with ﬁndings that
the DAT1 10-repeat allele is more strongly associated with AD/HD
C than AD/HD-I [e.g., Waldman et al., 1998]. Furthermore, this
meta-analysis suggests that reducing the AD/HD phenotypic het
erogeneity may lead to the discovery of AD/HD etiological subtypes
or possibly distinct disorders [e.g., Milich et al., 2001]. No other
sample characteristics accounted for a signiﬁcant proportion of
true between studies variance.
In addition to sample characteristics, the association between
study methodology and magnitude of effect size was explored. In
contrast to Li et al. [2006], case–control studies did not have a
signiﬁcantly larger effect size than family-based studies, but there
was a trend in this direction. Given that results of case–control
studies may be biased by population stratiﬁcation [Cardon and Bell,
2001], the relationship between 7R allele frequencies in the AD/HD
and control samples and OR was examined. The allele frequency in
the AD/HD sample was not related to the observed OR whereas the
allele frequency in the control population did predict observed OR
and accounted for close to all of the systematic variability of
observed ORs between case–control studies. Given that the DRD4
allele frequencies vary substantially across ethnic groups [e.g.,
Chang et al., 1996] and that the association between the 7R allele
and AD/HD may be dynamic [Shaw et al., 2007], the appropriate
ness of the control sample in case–control studies is of critical
importance. Failure to appropriately control for such character
istics may have inﬂuenced the variability in ﬁndings.
These ﬁndings provide guidance for further study. First, indi
cators for the quality of AD/HD phenotyping are underreported in
the literature. Future studies would be enhanced by: including
information related to the psychometric properties of their assess
ments; describing how assessments are combined to form a diag
nosis; reporting how many cases and controls did not meet criteria
for study inclusion; and by presenting descriptive sample statistics
for both cases and controls. In terms of genotyping, few studies

adequately reported tests of Hardy–Weinberg equilibrium [Gizer
et al., 2009]. Future studies should report such information as it
may help to explain variability between study ﬁndings. Though this
meta-analysis included a relatively large number of samples, values
for covariates of interest were often unavailable. For instance, like
AD/HD subtype, differences in the rates of Conduct Disorder
within and between samples may account for heterogeneity in
candidate gene association studies [Thapar et al., 2006]; however,
too few studies presented the rate of conduct disorder within their
sample to be examined in this meta-analysis. In addition, values of
covariates for TDT studies were attained from summary statistics
that were based on the sample at-large and not only individuals
included in the TDT analysis. Future research should stratify results
based on potential moderating variables [Li et al., 2006] from the
sample or sub-sample for which the results are based.
These ﬁndings also need to be considered in light of the limi
tations inherent in meta-regression analysis and subgroup analysis
[see Thompson and Higgins, 2002 for a review]. First, values for
moderating variables were not randomly assigned to studies; thus,
relationships may be related to confounding bias. Second, meta
regression analyses examining sample characteristics deal with
sample averages between studies and not individual level data
within studies, thus observed relationships between studies are not
necessarily found within studies (e.g., ecological bias). For instance,
though some evidence suggests that the relationship between AD/
HD and the DRD4 7R allele may reduce with age [Shaw et al., 2007],
limited between study variability may have masked this association,
which may be present within studies. This limitation can be
attenuated through large collaborative efforts or by data stratiﬁed
by moderating variables of interest. Finally, a practical limitation of
meta-analysis and especially meta-regression is that access to
observed effect size, its variance, and values for covariates are
necessary.
Despite these limitations, such ﬁndings support the argument
[e.g., Milich et al., 2001] that AD/HD-C and AD/HD-I (with few to
no hyperactive–impulsive symptoms) may result from distinct
etiological pathways. Further delineating samples based on symp
toms related to Sluggish Cognitive Tempo [e.g., McBurnett et al.,
2001] may allow for greater speciﬁcity in identifying shared and
distinct pathways to distinct behavioral phenotypes. These ﬁndings
also suggest that reducing the phenotypic variability within AD/HD
may help to increase statistical power to detect candidate genes in
molecular genetic studies.
By pooling summary data from a relatively large number of
association studies, evidence suggests that the DRD4 7R allele is
more strongly related to AD/HD-C compared to AD/HD-I. These
ﬁndings suggest that etiological theories of AD/HD, which are
primarily based on AD/HD-C individuals, may fall short in identi
fying appropriate candidate susceptibility genes for AD/HD-I.
Additionally, given that the majority of genetic studies of AD/HD
are conducted on clinical samples, which are disproportionally
diagnosed with AD/HD-C [Lahey et al., 1994], such investigations
may lack sufﬁcient power to identify unique vulnerability genes
associated with AD/HD-I. Therefore, exploratory genome wide
association studies may have the potential to identify genes that are
more replicable and have a stronger association [Gizer et al., 2009]
for this group of individuals. To guide candidate gene studies,

future research should look to elucidate the neurobiological under
pinnings of severe inattentive symptomatology in the absence of
hyperactivity–impulsivity so that the genetic underpinnings of this
symptom presentation may be better understood. To the extent that
AD/HD-C and AD/HD-I (with few or no hyperactivity–impulsivity
symptoms) have unique etiological pathways, there would be
sufﬁcient evidence to categorize these AD/HD subtypes as separate
disorders [e.g., Milich et al., 2001].
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